
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.47 | 19.341563786 | 2.43 | 2.8621 | 2.36 | 35924 | 2.69967257 | CS |
4 | -0.4 | -12.1212121212 | 3.3 | 3.53 | 2.01 | 38186 | 2.76978167 | CS |
12 | -2.04 | -41.2955465587 | 4.94 | 7.3 | 2.01 | 263127 | 5.88636078 | CS |
26 | -4.3 | -59.7222222222 | 7.2 | 7.59 | 2.01 | 134252 | 5.8738583 | CS |
52 | -14.59 | -83.4190966266 | 17.49 | 18.5 | 2.01 | 153665 | 10.01619293 | CS |
156 | -44.85 | -93.9267015707 | 47.75 | 92.5 | 2.01 | 195492 | 23.60633541 | CS |
260 | -391.35 | -99.2644261256 | 394.25 | 449.75 | 2.01 | 224021 | 71.17194383 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions